---
title: Plasma Cell Disorders
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Huppert's Notes]]

# Plasma Cell Disorders #ðŸš§ æ–½å·¥ä¸­

### Plasma Cell Disorders

A framework for plasma cell disorders:

â€¢Â Â Â Spectrum of disease: See Figure 7.6

-Â Â Â Monoclonal gammopathy of uncertain significance (MGUS) (asymptomatic)

-Â Â Â Smoldering multiple myeloma (asymptomatic): <3g/dL M-spike or 10% plasma cells on bone marrow biopsy

-Â Â Â Active multiple myeloma

-Â Â Â Plasma cell leukemia

-Â Â Â Amyloidosis: Some clones make light chains that are amyloidogenic â€“ can occur with any of the four above

##### Monoclonal gammopathy of undetermined significance (MGUS)

â€¢Â Â Â Pathophysiology: Asymptomatic pre-malignant plasma cell proliferation that typically occurs in elderly patients. See increase in serum protein with M-spike on SPEP, but no other associated symptoms. Fewer than 20% of patients with MGUS develop multiple myeloma (MM), but almost all patients with MM have preceding MGUS.

â€¢Â Â Â Diagnostic criteria:

-Â Â Â Serum monoclonal Ig protein (M-spike) <3 g



**FIGURE 7.6: Spectrum of plasma cell dyscrasias**.

-Â Â Â Bone marrow clonal plasma cells <10%

-Â Â Â No end organ damage (i.e., no CRAB criteria)

â€¢Â Â Â Work-up:

-Â Â Â CBC, CMP, Mg2\+, phosphorus, LDH, total immunoglobulins (IgA, IgG, IgM)

-Â Â Â Serum protein electrophoresis (SPEP) â€“ *quantifies* a monoclonal abnormal protein (M-spike)

-Â Â Â Immunofixation (IFE) â€“ *classifies* the abnormal protein

-Â Â Â Serum free light chain (sFLC) â€“ Detects LOW levels of free light chains in serum, so it can pick up lighter proteins. Note: In CKD, increased K:L ratio up to 3 can be normal due to â†“clearance of FLC

-Â Â Â UA, urine spot protein/Cr.

-Â Â Â 24hr UPEP â€“ *quantifies* urine M protein, UIFE â€“ *classifies* abnormal protein, urine free light chains (Bence Jones protein)

-Â Â Â Beta-2-microglobulin: Strong prognostic value but non-specific

-Â Â Â Skeletal survey (long bones, skull) to rule out lytic lesions suggesting multiple myeloma. Alternatively, can consider low dose whole body CT scan or MRIs.

â€¢Â Â Â Treatment: None needed, observation. Monitoring depends on risk factors (Ig type, M-spike, light chains).

##### Multiple myeloma (MM)

â€¢Â Â Â Pathophysiology: Malignant proliferation of a single plasma cell line that makes a monoclonal immunoglobulin â€“ most often large amounts IgG or IgA

â€¢Â Â Â Clinical features: Often patients in 60s with fractures or bone pain

-Â Â Â Diagnostic criteria = **SLiM-CRAB**

**â€¢**Â Â Â **S**ixty percent plasma cells on bone marrow biopsy

**â€¢**Â Â Â Serum Free **Li**ght chain ratio >100

**â€¢**Â Â Â **M**RI with >1 focal lesion (plasmacytoma)

**â€¢**Â Â Â Hyper**C**alcemia (>10.5 mg/dL)

**â€¢**Â Â Â **R**enal insufficiency (immunoglobulins precipitate in renal tubules - Bence Jones protein, Cr >2mg/dL without an alternative diagnosis)

**â€¢**Â Â Â **A**nemia (Hgb<10 g/dL without an alternative diagnosis)

**â€¢**Â Â Â **B**ony disease (â€œpunched outâ€ lytic bone lesions or osteoporosis). Bone pain most common presenting symptom.

-Â Â Â Other clinical features:

**â€¢**Â Â Â Amyloidosis: Kappa chain accumulation â†’ carpal tunnel syndrome


**TABLE 7.4** â€¢ R-ISS Staging for Multiple Myeloma: Criteria and Prognosis




**â€¢**Â Â Â Infection: Lack of immunoglobulin diversity can lead to increased risk of infection

â€¢Â Â Â Diagnosis: Need labs (SPEP, SFLC), imaging (usually PET/CT), and bone marrow biopsy

-Â Â Â Serum monoclonal protein present (M-spike >3g)

-Â Â Â Bone marrow clonal plasma cells >10%

-Â Â Â End organ damage present (i.e., SLiM-CRAB)

-Â Â Â Other common findings:â†‘ESR, â†‘serum protein. Smear: RBC = Rouleaux (â€œstacks of RBCsâ€ â€“ RBCs stick together due to increased plasma proteins)

â€¢Â Â Â Staging: Revised-International Staging System (R-ISS): Uses Beta-2-microglobulin, albumin, LDH, and chromosomal abnormalities to predict overall and progression-free survival at 5 yr. See Table 7.4.

â€¢Â Â Â Treatment: Typically, chemotherapy followed by autologous stem cell transplant

-Â Â Â Classes of therapy:

**â€¢**Â Â Â Proteasome inhibitors: Bortezomib, carfilzomib

**â€¢**Â Â Â Immunomodulatory agents: Lenalidomide

**â€¢**Â Â Â Monoclonal Antibody: Daratumumab (anti-CD38 targeting MM cells)

-Â Â Â Common regimens:

**â€¢**Â Â Â Hyper CD (cyclophosphamide \+ dexamethasone) â€“ commonly used for rapid reduction in patients with a high disease burden

**â€¢**Â Â Â RVD: lenalidomide (Revlimid), bortezomib (Velcade), dexamethasone

**â€¢**Â Â Â KRD: carfilzomid (Kyprolis), lenalidomide (Revlimid), dexamethasone

**â€¢**Â Â Â Daratumumab, lenalidomide, dexamethasone

##### WaldenstrÃ¶m macroglobulinemia

â€¢Â Â Â Pathophysiology: Malignant clonal proliferation of IgM producing plasmacytoid lymphocytes

â€¢Â Â Â Clinical features: Similar to MM, but IgM protein is larger and â€œstickier,â€ so it causes more symptoms of hyperviscosity syndrome (up to 30% of patients). Cold cryoglobulinemia in 10% of patients.

â€¢Â Â Â Treatment: Plasmapheresis may be needed to emergently manage hyperviscosity. Treatment usually includes rituximab.

##### AL amyloidosis

â€¢Â Â Â Pathophysiology: Immunoglobulin light chain amyloid from malignant clonal proliferation of plasma cells (e.g., MM, WaldenstrÃ¶m). The proteins deposit in tissues and cause end organ damage.

â€¢Â Â Â Clinical features: Nephrotic syndrome, restrictive cardiomyopathy, neuropathy

â€¢Â Â Â Diagnosis: Biopsy (often fat pad biopsy) to look for deposition of amyloid protein. SPEP will show an M-spike and serum free light chains will show an abnormal sFLC ratio.

â€¢Â Â Â Treatment: Treat underlying plasma cell disorder. Consider autologous stem cell transplant.

---
title: "PLASMA CELL DISORDERS"
date: "2023-02-08"
enableToc: false
---

> [!info] 
> 
> ðŸŒ±ä¾†è‡ª: [[Pocket Oncology]]

# PLASMA CELL DISORDERS
MGUS and Multiple Myeloma (MM)
WaldenstrÃ¶m Macroglobulinemia
Amyloidosis
